$322 Million is the total value of Exane Asset Management's 97 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| C | CITIGROUP INC COM NEWstock | $9,301,250,000 | +2.3% | 125,000 | 0.0% | 2.89% | +62.6% | |
| BOBE | BOB EVANS FARMS INC COMstock | $788,200,000 | +1.7% | 10,000 | 0.0% | 0.24% | +62.3% | |
| DVMT | DELL TECHNOLOGIES INC COM CL Vstock | $696,326,000 | +5.3% | 8,567 | 0.0% | 0.22% | +67.4% | |
| XCRA | XCERRA CORP COMstock | $25,806,000 | -0.6% | 2,636 | 0.0% | 0.01% | +60.0% | |
| JBGS | JBG SMITH PPTYS COMstock | $23,269,000 | +1.5% | 670 | 0.0% | 0.01% | +75.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UBS GROUP AG SHS | 25 | Q1 2023 | 31.8% |
| T-MOBILE US INC COM | 25 | Q3 2023 | 23.9% |
| GOLDMAN SACHS GROUP INC COM | 16 | Q3 2023 | 14.3% |
| BRISTOL-MYERS SQUIBB CO COM | 15 | Q1 2020 | 9.9% |
| CITIGROUP INC COM NEW | 15 | Q4 2022 | 18.8% |
| GILEAD SCIENCES INC COM | 15 | Q2 2019 | 8.9% |
| DBV TECHNOLOGIES S A SPONSORED ADR | 13 | Q2 2019 | 1.7% |
| CYTOMX THERAPEUTICS INC COM | 13 | Q4 2020 | 1.3% |
| MICROSOFT CORP COM | 12 | Q4 2022 | 19.4% |
| TIM PARTICIPACOES S A SPONSORED ADR | 12 | Q3 2019 | 12.2% |
View Exane Asset Management's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-23 |
| 13F-HR | 2024-01-24 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-17 |
| 13F-HR/A | 2023-05-11 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-17 |
| 13F-HR | 2022-10-24 |
| 13F-HR | 2022-07-15 |
| 13F-HR | 2022-04-21 |
View Exane Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.